None listed
Conditions
Interventions
Group A:Intravenous alfentanil 15 µg/kg, remimazolam 0.33 mg/kg
Group B:Intravenous remifentanil 2 µg/kg, remimazolam 0.33 mg/kg
Group C:Intravenous alfentanil 15 µg/kg, propofol 2.5 mg/kg
Group D:Intravenous remifentanil 2 µg/kg, propofol 2.5 mg/kg
Sponsors
The Second Affiliated Hospital of Zunyi Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. Patients receiving painless fibrobronchoscopy; 2. Aged 18~65 years, no gender limit; 3. ASA?~?; 4. BMI: 18~30 kg/m^2.
Exclusion criteria
Exclusion criteria: 1. Contraindications to general anesthesia; 2. Cardiac function > Grade 3 with a history of severe cardiovascular disease; Unstable angina pectoris, or myocardial plug within the last 6 months; 3. Acute upper respiratory tract infection, asthma attack or acute severe laryngeal disease; 4. Hypertension with unsatisfactory blood pressure control (recumbent systolic blood pressure >=180 mmHg, and/or diastolic blood pressure >=110 mmHg during screening); 5. A history of alcohol abuse and chronic use of sedatives and opiates; 6. Pregnancy or lactation; 7. Liver and kidney dysfunction; 8. History of mental disorders; 9. The researcher decided that it was not suitable to participate in the experiment; 10. The treatment time of fibrobronchoscopy was more than 1 hour.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Sedation success rate;The number of drug refills; | — |
Secondary
| Measure | Time frame |
|---|---|
| The observer's assessment of alertness/sedation scale;Postoperative recovery time;Vital signs and perioperative adverse events;Time of leave;Ramsay sedation score; | — |
Countries
China
Contacts
Public ContactWang Zhao
The Second Affiliated Hospital of Zunyi Medical University
Outcome results
None listed